By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares ...

Chris Patterson, a former KFD captain, fell off a ladder around 2 years ago while responding to a call and has been in pain ...

The plaintiff's attorney said the biggest hurdle in the case had to do with proving causation, since the plaintiff had ...

The numbers Yee is talking about are from a new study released by a spinal surgeon, Dr. Brian Kwon, who noticed an alarming ...

The New Haven, Conn., biopharmaceutical company said Monday that taldefgrobep had shown clinically meaningful improvements in motor function in spinal muscular atrophy patients, but the treatment arm ...

Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

Kessler Foundation researchers have developed robust measures of neighborhood economic factors to study how social determinants influence health outcomes after spinal cord injury (SCI).

In a breakthrough towards redefining pain management, a team of spine surgeons and pain specialists at Apollo Cancer Centre ...

OVER 2,000 people participated in a charity fun run themed “Together We Care” aimed at raising awareness and support for individuals affected by spinal muscular atrophy (SMA).